Literature DB >> 31208920

Minimal Clinically Important Difference and Substantial Clinical Benefit Values for a Pain Visual Analog Scale After Hip Arthroscopy.

RobRoy L Martin1, Benjamin R Kivlan2, John J Christoforetti3, Andrew B Wolff4, Shane J Nho5, John P Salvo6, Thomas J Ellis7, Geoff Van Thiel8, Dean Matsuda9, Dominic S Carreira10.   

Abstract

PURPOSE: To define minimal clinically important difference (MCID) and substantial clinical benefit (SCB) values for a pain visual analog scale (VAS) in patients undergoing hip arthroscopy for femoroacetabular impingement or chondrolabral pathology.
METHODS: This was a retrospective review of prospective collected data on patients having hip arthroscopy for femoroacetabular impingement and/or chondrolabral pathology. On initial assessment and follow-up between 335 and 395 days postsurgery, subjects completed a pain VAS and categorical self-rating of function. MCID was calculated using one-half the standard deviation (SD) of the change in 1-year pain VAS values. Receiver operator characteristic analysis was performed to determine SCB values. A change in SCB value was determined based on change in categorical self-rating of function to create "improved" and "not improved" groups. Absolute postoperative SCB scores were calculated to determine scores that would be associated with "normal" or "abnormal" function ratings.
RESULTS: Of 1,034 eligible patients, 733 (71%) met the inclusion criteria, with 537 (73%) women and 196 (27%) men having a mean age of 35.3 years (SD 13). At a mean of 352 (SD 21) days postsurgery, 536 (73%) were in the improved group and 197 (27%) in the not improved group. MCID was -15.0 mm. A change of -22.7 mm on the pain VAS was able to identify those that improved with high sensitivity (0.74) and specificity (0.63). Values of ≤10.4 mm and ≥29.0 mm were cutoffs identifying subjects that rated their function as normal or abnormal, respectively, with high sensitivity (0.79 and 0.76) and specificity (0.88 and 0.76).
CONCLUSIONS: This study provides surgeons with information to help interpret pain VAS values at a follow-up period ranging from 335 to 395 days with MCID and SCB values of -15.0 mm and -22.7 mm, respectively. Additionally, a patient who assesses a pain level at ≤10.4 mm is likely to have a normal rating of function, whereas a patient who assesses a pain level at ≥29.0 mm is likely to have an abnormal rating of function. LEVEL OF EVIDENCE: III, retrospective comparative study.
Copyright © 2019. Published by Elsevier Inc.

Entities:  

Mesh:

Year:  2019        PMID: 31208920     DOI: 10.1016/j.arthro.2019.02.032

Source DB:  PubMed          Journal:  Arthroscopy        ISSN: 0749-8063            Impact factor:   4.772


  5 in total

1.  Outcomes of Surgical Management of Borderline Hip Dysplasia: A Systematic Review.

Authors:  Cameron Barton; Elizabeth Scott; Zain M Khazi; Michael Willey; Robert Westermann
Journal:  Iowa Orthop J       Date:  2019

2.  Conservative management acutely improves functional movement and clinical outcomes in patients with pre-arthritic hip pain.

Authors:  Ryan P McGovern; RobRoy L Martin; Amy L Phelps; Benjamin R Kivlan; Beth Nickel; John J Christoforetti
Journal:  J Hip Preserv Surg       Date:  2020-01-22

3.  Altered activity of pain processing brain regions in association with hip osteoarthritis.

Authors:  P Railton; A J Delaney; B G Goodyear; J Matyas; S Lama; G R Sutherland; J N Powell
Journal:  Sci Rep       Date:  2022-02-18       Impact factor: 4.379

4.  Extent of Cam Resection Relative to Epiphyseal Line and Its Association With Clinical Outcomes After Arthroscopic Treatment for Femoroacetabular Syndrome.

Authors:  Fan Yang; Hong-Jie Huang; Zi-Yi He; Yan Xu; Xin Zhang; Jian-Quan Wang
Journal:  Orthop J Sports Med       Date:  2022-09-29

5.  What is the Role of Kinesiophobia and Pain Catastrophizing in Outcomes After Hip Arthroscopy for Femoroacetabular Impingement Syndrome?

Authors:  Ian M Clapp; Benedict U Nwachukwu; Edward C Beck; Jonathan P Rasio; Thomas Alter; Bradley Allison; Shane J Nho
Journal:  Arthrosc Sports Med Rehabil       Date:  2020-01-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.